PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
25932137-0	2015	Paroxetine alleviates rat limb post-ischemia induced allodynia through GRK2 upregulation in superior cervical ganglia.	Paroxetine	0-10	G protein-coupled receptor kinase 2	Rattus norvegicus	71-75	
25932137-2	2015	Here, we investigated the effects of paroxetine (a selective serotonin reuptake inhibitor and GRK2 inhibitor) on GRK2 expression in superior cervical ganglion (SCG) in a rat model of complex regional pain syndrome type I (CRPS-I).	Paroxetine	37-47	G protein-coupled receptor kinase 2	Rattus norvegicus	113-117	
25932137-5	2015	After paroxetine administration, the ipsilateral 50% PWTs at day 2, 7, 14, and 21 were significantly higher than those in control group; The GRK2 protein and mRNA levels in ipsilateral SCGs were also significantly up-regulated after day1; The ipsilateral cold allodynia scores were significantly reduced after day7.	Paroxetine	6-16	G protein-coupled receptor kinase 2	Rattus norvegicus	141-145	
25932137-6	2015	No significant differences were found in the contralateral 50% PWTs, cold allodynia scores, and GRK2 protein level except GRK2 mRNA levels increased significantly at day1-day7 after paroxetine administration.	Paroxetine	182-192	G protein-coupled receptor kinase 2	Rattus norvegicus	122-126	
25932137-7	2015	Therefore, a transient decrease of GRK2 expression in SCG neurons might be involved in the development and maintenance of allodynia in CRPS-I and paroxetine might alleviate this allodynia through GRK2 protein upregulation in SCGs.	Paroxetine	146-156	G protein-coupled receptor kinase 2	Rattus norvegicus	196-200	
28349925-3	2017	A GRK2 inhibitor, paroxetine protects the joints from inflammation and destruction, primarily through inhibition of both CD4+ helper T (Th) cell and CD8+ cytotoxic T (Tc) cell migration to synovial tissue.	Paroxetine	18-28	G protein-coupled receptor kinase 2	Rattus norvegicus	2-6	
34608562-9	2022	In vessels, there was no change in genetic transcription (RNAseq) or protein expression (immunofluorescence); however, inhibition of GRK2 (paroxetine) led to improved vasodilation to norepinephrine in the old control (OC) and O + SVF, indicating greater GRK2 functional inhibition of beta1-AR in aging.	Paroxetine	139-149	G protein-coupled receptor kinase 2	Rattus norvegicus	133-137	
33859345-8	2022	In CIA rats, administration of paroxetine to inhibit GRK2 effectively improved the symptoms and clinic parameters with significantly reduced joint synovium inflammation and bone destruction.	Paroxetine	31-41	G protein-coupled receptor kinase 2	Rattus norvegicus	53-57	
34386323-6	2021	CP-25 and GRK2 inhibitors (paroxetine or GSK180736A) inhibited the abnormal proliferation of FLS in RA patients and CIA rats by down-regulating GRK2 translocation to EP4 receptor.	Paroxetine	27-37	G protein-coupled receptor kinase 2	Rattus norvegicus	144-148	
33434531-4	2021	Inhibition of GRK2 by paroxetine (PAR) or genetic depletion of GRK2 restored A3AR distribution and prevented Th17 cell differentiation.	Paroxetine	22-32	G protein-coupled receptor kinase 2	Rattus norvegicus	14-18	
33434531-4	2021	Inhibition of GRK2 by paroxetine (PAR) or genetic depletion of GRK2 restored A3AR distribution and prevented Th17 cell differentiation.	Paroxetine	34-37	G protein-coupled receptor kinase 2	Rattus norvegicus	14-18	
30226217-5	2018	GRK2 was inhibited by IP injection of paroxetine, a selective GRK2 inhibitor, after STZ injection.	Paroxetine	38-48	G protein-coupled receptor kinase 2	Rattus norvegicus	0-4	
30226217-5	2018	GRK2 was inhibited by IP injection of paroxetine, a selective GRK2 inhibitor, after STZ injection.	Paroxetine	38-48	G protein-coupled receptor kinase 2	Rattus norvegicus	62-66	
30226217-9	2018	Inhibition of GRK2 with paroxetine ameliorated Akt/eNOS signaling, restored NO production, downregulated NADPH oxidase, subsequently inhibited ROS generation and apoptosis, and ultimately preserved erectile function.	Paroxetine	24-34	G protein-coupled receptor kinase 2	Rattus norvegicus	14-18